Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley reported a sale of company stock. On January 22, 2026, he sold 13,578 shares of common stock at a weighted average price of $5.3309 per share. According to the filing, the sale was made to cover tax obligations associated with the vesting of restricted stock awards, meaning it was tied to equity compensation rather than an open-market discretionary sale of his full holdings. After this transaction, O'Malley beneficially owned 451,134 shares of Abeona common stock directly.
Abeona Therapeutics (ABEO) has a holder planning to sell 12,610 shares of common stock through broker Stifel Nicolaus & Company on or about 01/22/2026 on the Nasdaq market, with an aggregate market value of $66,658.00. The notice states that there were 54,191,361 shares of this class outstanding. The shares to be sold relate to restricted stock units that were acquired from the issuer on 01/21/2026 as equity compensation, in an amount of 25,048 shares. The person filing represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Abeona Therapeutics investor plans small stock sale under Rule 144. A notice was filed to potentially sell 18,666 shares of Abeona Therapeutics common stock through broker Stifel Nicolaus & Company on or after 01/22/2026 on the Nasdaq market. The aggregate market value of the proposed sale is listed as $99,507.00.
The shares relate to equity compensation. The filer acquired 48,169 shares of common stock on 01/21/2026 through restricted stock units granted by the issuer, with “equity compensation” described as the form of payment. The filing also notes that 51,191,361 shares of Abeona common stock were outstanding, providing context for the size of the planned sale.
ABEO has a planned insider sale under Rule 144. A holder has filed to sell 13,578 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $73,233.00. The shares relate to an award of 38,535 restricted stock units the holder acquired from the issuer on 01/21/2026 as equity compensation, with the planned sale date around 01/22/2026 on the Nasdaq exchange.
The filing notes that 54,191,361 shares of common stock were outstanding, providing context for the size of the planned sale relative to the company’s total share count.
Abeona Therapeutics (ABEO) insider Vishwas Seshadri has filed a notice of proposed stock sales under Rule 144. The filing covers 69,832 shares of common stock to be sold through Stifel Nicolaus & Company on the Nasdaq exchange, with an aggregate market value of 372,267.00. The filing notes that 54,191,361 shares of common stock were outstanding.
The securities to be sold were acquired on 01/21/2026 as 158,811 restricted stock units from the issuer, characterized as equity compensation, with the payment date listed as 01/22/2026. The document also reports that Seshadri sold 25,000 shares of common stock on 12/29/2025, generating gross proceeds of 132,740.00 over the prior three months.
Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.
The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.
A stockholder has filed a notice of intent to sell 13,500 shares of common stock, with an aggregate market value of $70,574, through broker Stifel Nicolaus & Company Inc. on or around 01/21/2026 on the Nasdaq exchange. These shares were acquired from the issuer on 07/08/2025 as restricted stock units granted as equity compensation, and became payable in shares on the same date.
Over the past three months, the person for whose account the securities are to be sold has already sold 15,000 shares of common stock, generating $71,168 in gross proceeds. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
Abeona Therapeutics reported an insider equity award to its Chief Financial Officer, Joseph Walter Vazzano. On January 20, 2026, he received 133,595 shares of common stock as restricted stock at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase. According to the disclosure, these restricted shares will vest in three equal installments on January 20, 2027, January 20, 2028, and January 20, 2029. Following this grant, Vazzano directly beneficially owns 587,226 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. disclosed an equity grant to its Chief Executive Officer and director, Vishwas Seshadri. On January 20, 2026, he received 365,422 shares of common stock as restricted stock at a price of $0.00 per share. After this award, he beneficially owned 1,530,240 shares of Abeona common stock in total.
The restricted stock will vest in three equal installments, with one-third of the shares scheduled to vest on each of January 20, 2027, January 20, 2028, and January 20, 2029, aligning the CEO’s compensation with the company’s multi‑year performance.
Abeona Therapeutics reported an insider equity award for its SVP and Chief Legal Officer, Brendan M. O'Malley. On January 20, 2026, he received 113,949 shares of common stock as restricted stock at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the final third on January 20, 2029. Following this award, O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.